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ntravascular Ultrasound Analysis of
olymer-Based Paclitaxel-Eluting Stents
ith great interest I read the report by Weissman et al. (1) regarding
ntravascular ultrasound (IVUS) analysis of polymer-based
aclitaxel-eluting stents. The investigators stated in the text that
positive remodeling assessed as the absolute increase in the
xternal elastic membrane volume over time tended to be slightly
ore prominent with the TAXUS stent (7.66  48.64 mm3 vs.
12.29  36.05 mm3, respectively, p  0.064).” Also Figure 1
uggested positive remodeling in the TAXUS stent. However,
able 2 of their article (1) shows an inconsistent result, that is,
ecrease of external elastic membrane volume in the TAXUS-stent
roup (283  91 mm3 at postimplantation vs. 280  89 mm3 at
ine-month follow-up). Because a previous IVUS analysis has also
uggested positive remodeling in the TAXUS stent (2), it may be
f great importance to better clarify this result.
Hideaki Kaneda, MD
Cardiology and Catheterization Laboratories
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EPLY
e appreciate Dr. Kaneda’s astute observation about the data
ontained in our report (1) on the intravascular ultrasound (IVUS)
esults from TAXUS-IV. It is indeed true that there was a trend for
he vessel receiving a TAXUS stent to demonstrate positive remod-
ling, similar to prior drug-eluting stent (DES) reports. The analysis
or remodeling used only TAXUS and non-TAXUS patients with
omplete volumetric IVUS data of the external elastic membrane
EEM) throughout the stent length at both the time of stent
mplantation and at follow-up. As it states in the Methods section,
Volumes were calculated only if the vascular interface was visualized
very millimeter throughout the stent” (i.e., we did not extrapolate the
EM border for images in which it was not visualized). Thus, not all
atients with EEM volume data at stent implantation had EEM
olume data at follow-up, and vice-versa. Table 2 of the study (1)
eports all the volume data at one time point (postimplantation or
ollow-up) and the statistical analysis for change (and Figure 1 of the
eport [1] displaying change over time) used only patients that had taired postimplantation and follow-up EEM volume data. Hence, the
esults of a trend toward positive remodeling in the TAXUS stent are
ndeed accurate and in concordance with other DES studies.
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estenosis, Statistics,
nd Reasonable Inferences
e appreciate the accompanying editorial (1) to our recent report
ntitled “Relationship Between Angiographic Late Loss and Tar-
et Lesion Revascularization After Coronary Stent Implantation:
nalysis From the TAXUS-IV Trial” (2) but we wish to clarify
everal apparent misconceptions. Our principal messages are that
n the era of drug-eluting stents (DES), it is not only the mean
alue but also the shape of the distribution curve (variance and
kewedness) that will determine the population target lesion
evascularization (TLR), and that with a homogeneous response
n-stent late losses up to about 0.75 mm may provide acceptable
linical results (2). That DES may have rightward skewed late loss
istograms has been previously reported (3). The fact that the
ndividual patient late loss/TLR relationship is curvilinear with an
pparent inflection point, rather than linear, had not been reported
nd is a novel and unique observation that has since been replicated
n several other DES trials (DELIVER, ENDEAVOR-II). Most
mportantly, given the rightward skew in patient population data
een in all these trials (including the pivotal SIRIUS trial of the
irolimus-eluting stent), a certain lower level or “floor” of TLR
ay be unavoidable, somewhat independent of the mean late loss.
Moreover, recent data reported at the most recent American
ollege of Cardiology meetings substantiate our findings. The
NDEAVOR-II trial, with a considerably higher mean late loss
0.62 mm) but with rather a homogeneous effect (standard
eviation of late loss 0.46), reported a low TLR of 4.6% with the
BT-578-eluting stent. The large-scale REALITY trial, compar-
ng the sirolimus-eluting and paclitaxel-eluting stents, found
ignificantly greater in-stent late loss with the latter (0.09 vs. 0.31
m, respectively, p  0.001), but nearly identical eight-month
LR rates (5.0% vs. 5.4%, p  0.81). Thus, given the patient and
esion complexity studied in the pivotal DES trials to date, an
acceptable” TLR can be achieved with a relatively high in-stent
ate loss, providing that a homogeneous response is seen.
In addition, other variables beyond angiographic late loss that
ay affect TLR rates must be considered, including the inaccura-
ies and variability of quantitative measures of late loss. Variable
hresholds of patient angina perception, follow-up ischemia detec-
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zation and revascularization procedures will also minimize the
ractical relevance of any differences in late loss. In the end,
robably all would agree that, up to a point, less late loss is better,
ut the range of late loss that is associated with infrequent clinically
riven TLR may be wider than previously believed. Whether this
elationship holds in more complex and challenging lesion subsets
ill be analyzed in the TAXUS-V and -VI studies.
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EPLY
lthough we appreciate the interest by Dr. Ellis and colleagues toward
ur recent editorial comment (1), we fear a central concept was missed.
he argument that more late loss (as long as the absolute measure
emains below some arbitrary threshold) is irrelevant as a measure of
rug-eluting stent (DES) efficacy is both intuitively flawed and derived by
n erroneous extrapolation from individual patient-level observations to
ean late loss values. Across observed levels of mean late loss in recent
rials, incremental changes in late loss are associated with increasing
estenosis risk (2). The relationship of mean late loss values to clinical
estenosis does not follow the S-shaped curve presented by Dr. Ellis and
olleagues but instead is curvilinear without an obvious inflection point
2). Furthermore, results of randomized controlled clinical trials compar-
ng the Cypher and Taxus stents for treatment of coronary stenoses in
Table 1. Randomized Comparative Trials of C
Trial
Late Lumen Loss
(mm)
Cypher Taxus
ISAR-DIABETES 0.19 0.45
SIRTAX 0.13 0.25
REALITY 0.09 0.31
ISAR-DESIRE 0.10 0.26omplex patient subsets do not support the “threshold” premise (3–6).
lthough the ISAR–DIABETES, SIRTAX, REALITY, and ISAR–
ESIRE trials reported mean late loss values well below the 0.75 mm
threshold” for clinical significance set by Dr. Ellis and colleagues, the
bserved binary angiographic restenosis (BAR) and target lesion revas-
ularization (TLR) rates were increased in proportion to increases in late
oss (Table 1). If coronary stents are deployed in one million individuals
early, the relative percent differences in BAR and TLR observed in these
rials translate into large socioeconomic differences (50,000 more
evascularization procedures yearly) and clearly support the premise that
less is better” with respect to late lumen loss in the DES era.
As we predicted in our editorial, when DES with apparent
ubtle differences in late lumen loss are compared, differences in
ate clinical/angiographic outcome measures are magnified in those
atient cohorts with the greatest propensity for restenosis. Thus,
ate lumen loss remains a primary measure of stent efficacy, which
orrelates with late clinical/angiographic outcomes in the DES era.
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r Versus Taxus Stents
BAR
(%)
TLR
(%)
Cypher Taxus Cypher Taxus
6.9 16.5 6.4 12.0
6.7 11.9 4.8 8.3
9.6 11.1 5.0 5.4yphe14.3 21.7 8.0 19.0
